logo
  • PREVENTION
    • Sun Safety
    • Indoor Tanning
    • Early Detection
    • References
  • FIND A SPECIALIST
  • SQUAMOUS CELL SKIN CANCER
    • About
      • Overview
      • Images
      • Risk Factors
    • Diagnosis
    • Staging
      • High-Risk Features
      • A Practical Description
    • Treating
      • Treatment Options
      • Treatment By Stage
    • Living With
      • Secondary Prevention
      • Dealing With the Side Effects Of Therapy
    • Resources
  • BASAL CELL CARCINOMA
    • About
      • Overview
      • Images
      • Risk Factors
    • Diagnosis
    • Staging
      • High-Risk Features
      • A Practical Description
    • Treating
      • Treatment Options
      • By Stage
    • Living With
      • Secondary Prevention
      • Dealing With the Side Effects Of Therapy
    • Resources
  • MELANOMA
  • ASK AN EXPERT
  • ABOUT
  • PREVENTION
    • Sun Safety
    • Indoor Tanning
    • Early Detection
    • References
  • FIND A SPECIALIST
  • SQUAMOUS CELL SKIN CANCER
    • About
      • Overview
      • Images
      • Risk Factors
    • Diagnosis
    • Staging
      • High-Risk Features
      • A Practical Description
    • Treating
      • Treatment Options
      • Treatment By Stage
    • Living With
      • Secondary Prevention
      • Dealing With the Side Effects Of Therapy
    • Resources
  • BASAL CELL CARCINOMA
    • About
      • Overview
      • Images
      • Risk Factors
    • Diagnosis
    • Staging
      • High-Risk Features
      • A Practical Description
    • Treating
      • Treatment Options
      • By Stage
    • Living With
      • Secondary Prevention
      • Dealing With the Side Effects Of Therapy
    • Resources
  • MELANOMA
  • ASK AN EXPERT
  • ABOUT

The Skin Cancer Education and Research Foundation – Home › Forums

    • Immunotherapy
    • Topics
    • Posts
    • Last Post
    • Expectations for therapy
    • 6
    • 13
    • Adjuvant Immunotherapy in stage IIIA patients

      March 1, 2018 at 12:16 am

      Lisa Kottschade

    • Dosing and administration
    • 2
    • 14
    • Reply To: Infusion times

      February 15, 2018 at 3:41 pm

      Lisa Kottschade

    • Side-effect management
    • 12
    • 47
    • Reply To: ASCO/NCCN guidlines now out

      February 23, 2018 at 5:53 pm

      Mollie Reed

    • Reimbursement
    • 2
    • 12
    • Reply To: Reimbursement for infliximab

      February 17, 2018 at 11:10 pm

      Krista Rubin

    • Other
    • 8
    • 28
    • Reply To: Influenza and Tamiflu and Immunotherapy

      February 25, 2018 at 10:12 pm

      Kathleen Madden

  •  

    • Targeted therapy
    • Topics
    • Posts
    • Last Post
    • Expectations for therapy
    • 1
    • 2
    • Reply To: Targeted therapies for adjuvant therapy

      November 3, 2017 at 2:07 am

      Virginia Seery

    • Dosing and administration
    • 2
    • 4
    • New BRAF/MEK inhibitors coming to market

      March 1, 2018 at 12:20 am

      Lisa Kottschade

    • Side-effect management
    • 2
    • 5
    • Reply To: ? odd toxicity

      January 27, 2018 at 11:50 pm

      Krista Rubin

    • Reimbursement
    • 0
    • 0
    • December 19, 2017 at 7:44 pm

      LisaTushla

    • Other
    • 2
    • 7
    • Reply To: Adjuvant Treatment with Targeted Therapy

      February 23, 2018 at 5:43 pm

      Mollie Reed

  •  

    • Intralesional immunotherapy
    • Topics
    • Posts
    • Last Post
    • Expectations for therapy
    • 0
    • 0
    • No Topics

    • Dosing and administration
    • 1
    • 3
    • Reply To: Pharmacy and nurse roles

      December 24, 2017 at 4:06 pm

      Kathleen Madden

    • Infectious Precautions
    • 2
    • 9
    • Reply To: TVEC infection control practices

      February 11, 2018 at 12:00 am

      Krista Rubin

    • Side-effect management
    • 1
    • 8
    • Reply To: Ocular herpes

      January 5, 2018 at 2:54 am

      Virginia Seery

    • Reimbursement
    • 1
    • 1
    • December 8, 2017 at 4:58 pm

    • Other
    • 0
    • 0
    • No Topics

  •  

    • Living With Melanoma
    • Topics
    • Posts
    • Last Post
    • Alternative/complementary therapies
    • 1
    • 2
    • Reply To: Herbal medications

      November 30, 2017 at 8:08 pm

      Virginia Seery

    • Fertility
    • 1
    • 4
    • Reply To: Family planning

      February 16, 2018 at 4:44 pm

      Mollie Reed

    • Nutrition
    • 2
    • 5
    • Reply To: Sugar and melanoma

      January 31, 2018 at 8:43 pm

      Lisa Kottschade

    • Coordination of care
    • 1
    • 3
    • Reply To: Coordination with primary care

      January 4, 2018 at 8:17 pm

      Krista Rubin

    • Other
    • 3
    • 6
    • Reply To: Vaccines

      February 1, 2018 at 3:46 am

      Krista Rubin

  •  

Login

Log In
Register Lost Password

Latest Activity

  • New BRAF/MEK inhibitors coming to market
    topic by Lisa Kottschade
    March 1
    in Dosing and administration
  • Adjuvant Immunotherapy in stage IIIA patients
    topic by Lisa Kottschade
    March 1
    in Expectations for therapy
  • Influenza and Tamiflu and Immunotherapy
    reply by Kathleen Madden
    February 25
    in Other
  • ASCO/NCCN guidlines now out
    reply by Mollie Reed
    February 23
    in Side-effect management
  • hepatotoxicity
    reply by Mollie Reed
    February 23
    in Side-effect management
© 2020 Skin Cancer Education & Research Foundation. All rights reserved.
  • News
  • Contact
  • Terms
  • Privacy